GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Debt-to-Asset

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Debt-to-Asset : 1.35 (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Debt-to-Asset?

Parnell Pharmaceuticals Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $0.01 Mil. Parnell Pharmaceuticals Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $32.28 Mil. Parnell Pharmaceuticals Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2018 was $24.00 Mil. Parnell Pharmaceuticals Holdings's debt to asset for the quarter that ended in Dec. 2018 was 1.35.

Parnell Pharmaceuticals Holdings Debt-to-Asset Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Debt-to-Asset Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Debt-to-Asset
Get a 7-Day Free Trial 0.09 0.38 0.63 1.07 1.35

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Debt-to-Asset Get a 7-Day Free Trial 0.09 0.38 0.63 1.07 1.35

Competitive Comparison of Parnell Pharmaceuticals Holdings's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Debt-to-Asset falls into.


Parnell Pharmaceuticals Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Parnell Pharmaceuticals Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2018 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.007 + 32.282) / 24.003
=1.35

Parnell Pharmaceuticals Holdings's Debt-to-Asset for the quarter that ended in Dec. 2018 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.007 + 32.282) / 24.003
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Parnell Pharmaceuticals Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Debt-to-Asset
Comparable Companies
OWCP CXUS CANB CNABQ LITH APPB GSRX PCYN EVIO GENH ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Website
https://www.parnell.com
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.